{
    "clinical_study": {
        "@rank": "159948", 
        "acronym": "TNM", 
        "arm_group": [
            {
                "arm_group_label": "Maintenance treatment", 
                "arm_group_type": "Experimental", 
                "description": "Initial treatment Vinorelbine-Docetaxel Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks for 6 cycles\nFollowed by:\nOral Vinorelbine 60mg/m2 D1, D8 or 80mg/m2 D1, D8 (dose schedule at investigator's discretion) Every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue"
            }, 
            {
                "arm_group_label": "Observation arm", 
                "arm_group_type": "Experimental", 
                "description": "Initial treatment: Vinorelbine-Docetaxel Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks for 6 cycles\nPatients in the observation arm will not be administered any treatment after Vinorelbine-Docetaxel"
            }
        ], 
        "brief_summary": {
            "textblock": "This 2 arms study will assess the efficacy and safety of the Vinorelbine-Docetaxel\n      combination given as an initial upfront treatment (first line) to all metastatic breast\n      cancer patients enrolled. Patients having a disease control following initial treatment,\n      will be randomized to either oral Vinorelbine maintenance arm or Observation arm. The trial\n      will also compare the efficacy and safety of maintenance oral Vinorelbine versus\n      Observation."
        }, 
        "brief_title": "Maintenance Oral Vinorelbine or Observation After Vinorelbine-Docetaxel First Line Chemotherapy in Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Patients >=18 years of age\n\n          -  Histologically or cytologically confirmed adenocarcinoma of the breast that is    now\n             metastatic or locally-recurrent and inoperable with curative intent\n\n          -  Measurable and/or non-measurable disease\n\n          -  The patient's primary and/or metastatic tumor is HER2 neu negative\n\n          -  Documented metastatic disease previously untreated with palliative chemotherapy\n\n          -  Adjuvant or neo-adjuvant chemotherapy (including treatment with docetaxel or any\n             other chemotherapy) is allowed with a disease free survival of at least 6 months\n\n          -  No symptom or sign of brain metastasis\n\n        Exclusion Criteria:\n\n          -  Operable local recurrence\n\n          -  Ascites or pericardial effusion as only site of metastasis\n\n          -  Symptomatic peripheral neuropathy > grade 1 according to the NCI Common Toxicity\n             Criteria\n\n          -  Radiotherapy to all areas of evaluable disease within the previous 4 weeks\n\n          -  Disease significantly affecting absorption\n\n          -  Severe hepatic insufficiency\n\n          -  Patient previously treated with chemotherapy for their metastatic disease"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02144194", 
            "org_study_id": "CRG SE036"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Maintenance treatment", 
                    "Observation arm"
                ], 
                "description": "Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks x 6 cycles", 
                "intervention_name": "Vinorelbine-Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Navelbine", 
                    "Navelbine IV", 
                    "Navelbine Oral", 
                    "Taxotere"
                ]
            }, 
            {
                "arm_group_label": "Maintenance treatment", 
                "description": "Oral Vinorelbine 60mg/m2 or 80mg/m2 D1, D8 every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue (dose schedule is at investigator's discretion)", 
                "intervention_name": "Vinorelbine", 
                "intervention_type": "Drug", 
                "other_name": "Navelbine Oral"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vinorelbine", 
                "Vinblastine", 
                "Docetaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Oral Vinorelbine", 
            "Oral Chemotherapy", 
            "Metastatic Breast Cancer", 
            "Advanced Breast Cancer", 
            "Maintenance treatment"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Achrafieh", 
                        "country": "Lebanon", 
                        "state": "Beirut"
                    }, 
                    "name": "Hotel Dieu de France University Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saida", 
                        "country": "Lebanon"
                    }, 
                    "name": "Hammoud Hospital University Medical Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Lebanon"
        }, 
        "number_of_arms": "2", 
        "official_title": "TNM Trial: Upfront Docetaxel [T] and Alternating iv and Oral Vinorelbine [N] Followed, by Either Maintenance Oral Vinorelbine, or Observation for Advanced Breast Cancer", 
        "overall_contact": {
            "email": "drfadi.research@gmail.com", 
            "last_name": "Fadi Farhat, M.D"
        }, 
        "overall_official": [
            {
                "affiliation": "Hammoud Hospital University Medical Center", 
                "last_name": "Fadi Farhat, M.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hotel Dieu De France University Hospital", 
                "last_name": "Marwan Ghosn, M.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hotel Dieu de France University Hospital", 
                "last_name": "Georges Chahine, M.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hotel Dieu de France University Hospital", 
                "last_name": "Joseph Kattan, M.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Sahel General Hospital", 
                "last_name": "Nizar Bitar, M.D", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Lebanon: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time To Disease Progression of patients who are treated with Vinorelbine-Docetaxel followed by maintenance oral Vinorelbine vs patients treated with Vinorelbine-Docetaxel without maintenance treatment", 
            "safety_issue": "No", 
            "time_frame": "Up to 36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02144194"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Response Rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 months"
            }, 
            {
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 months"
            }, 
            {
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 months"
            }, 
            {
                "measure": "Number and percentage of participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Participants will be followed for the entired duration of the study, an expected average of 60 months"
            }, 
            {
                "measure": "3-Y Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 36 months"
            }
        ], 
        "source": "Cancer Research Group - Collaborative Group, Beirut, Lebanon.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cancer Research Group - Collaborative Group, Beirut, Lebanon.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}